BioSpace News Archive

Business

Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022

Ipsen, a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2022.

April 27, 2022
·
14 min read
Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center

Basilea Pharmaceutica Ltd. announced that it has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center, Inc., for a preclinical program on novel first-in-class broad spectrum antifungals with activity against difficult-to-treat mold infections.

April 27, 2022
·
3 min read
Policy

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has received a Notice of Allowance from the U.S. Patent and Trademark Office for Patent Application No. 15/303,121 entitled, “Modified Release Orally Administered Amino Acid Formulations.”.

April 27, 2022
·
5 min read
Spexis Annual General Meeting 2022

Spexis AG announced that its shareholders approved all proposals of the Board of Directors at the 25th Annual General Meeting with a significant majority.

April 27, 2022
·
2 min read
OKYO Pharma (“OKYO” or the “Company”) - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

OKYO Pharma Limited announced that two presentations will be given on OKYO drug candidates OK-101 and OK-201 at the Association for Research and Vision in Ophthalmology Annual Meeting, to be held on May 1-4, 2022 in Denver, CO and virtually on May 11-12, 2022.

April 27, 2022
·
4 min read
iXensor Receives Strategic Investment from Rohto Pharmaceutical with A Separate Technology Licensing Agreement

iXensor, the pioneer of mobile health, today announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder.

April 27, 2022
·
4 min read
Drug Development

Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer’s dementia by several years

BioArctic AB’s partner Eisai announced that an article about long-term health outcomes of the investigational anti-amyloid-beta protofibril antibody lecanemab in people living with early Alzheimer’s disease, using disease modeling, was published in the peer-reviewed journal Neurology and Therapy.

April 27, 2022
·
7 min read
Bionter AG secures $3 Million in Series Seed Financing Led by Dynamk Capital

Bionter AG, experts in sub-visible particle testing, announced the completion of a $3 million Series Seed financing from Dynamk Capital.

April 27, 2022
·
2 min read
Policy

Orexo’s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis

Orexo AB, announces that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI, a drug candidate for the treatment of systemic sclerosis, has been granted Orphan Drug Designation in the US by the Food and Drug Administration.

April 27, 2022
·
4 min read
Business

BioInvent International AB: Interim Report January-March 2022

The exciting translational data presented on BI-1808 at AACR clearly show why we are so enthusiastic about our ongoing clinical studies in solid tumors.

April 27, 2022
·
2 min read